Intensity Therapeutics, Inc. (INTS)
4.26
+0.01
(+0.24%)
USD |
NASDAQ |
Aug 31, 15:09
Intensity Therapeutics Enterprise Value : 3.085M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 3.085M |
| August 27, 2026 | 3.144M |
| August 26, 2026 | 3.910M |
| August 25, 2026 | 4.985M |
| August 24, 2026 | 4.558M |
| August 21, 2026 | 4.882M |
| August 20, 2026 | 4.940M |
| August 19, 2026 | 2.938M |
| August 18, 2026 | 2.967M |
| August 17, 2026 | 2.790M |
| August 14, 2026 | 2.231M |
| August 13, 2026 | 2.348M |
| August 12, 2026 | 2.820M |
| August 11, 2026 | 2.938M |
| August 10, 2026 | 3.203M |
| August 07, 2026 | 2.820M |
| August 06, 2026 | 3.085M |
| August 05, 2026 | 2.938M |
| August 04, 2026 | 2.879M |
| August 03, 2026 | 3.114M |
| July 31, 2026 | 2.790M |
| July 30, 2026 | 2.496M |
| July 29, 2026 | 3.320M |
| July 28, 2026 | 3.968M |
| July 27, 2026 | 4.027M |
| Date | Value |
|---|---|
| July 24, 2026 | 3.674M |
| July 23, 2026 | 3.615M |
| July 22, 2026 | 3.497M |
| July 21, 2026 | 3.527M |
| July 20, 2026 | 4.410M |
| July 17, 2026 | 4.558M |
| July 16, 2026 | 4.999M |
| July 15, 2026 | 4.823M |
| July 14, 2026 | 4.911M |
| July 13, 2026 | 5.058M |
| July 10, 2026 | 4.646M |
| July 09, 2026 | 5.029M |
| July 08, 2026 | 4.999M |
| July 07, 2026 | 4.646M |
| July 06, 2026 | 3.880M |
| July 02, 2026 | 3.055M |
| July 01, 2026 | 2.790M |
| June 30, 2026 | 2.643M |
| June 29, 2026 | 0.1079M |
| June 26, 2026 | 0.2731M |
| June 25, 2026 | 0.2222M |
| June 24, 2026 | 0.2222M |
| June 23, 2026 | 0.019M |
| June 22, 2026 | -0.1461M |
| June 18, 2026 | -0.1842M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.76B |
| Oncolytics Biotech, Inc. | 103.10M |
| Sangamo Therapeutics, Inc. | 58.24M |
| Sarepta Therapeutics, Inc. | 2.461B |
| Anixa Biosciences, Inc. | 103.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.007M |
| Total Expenses (Quarterly) | 3.007M |
| EPS Diluted (Quarterly) | -1.111 |
| Earnings Yield | -113.4% |
| Normalized Earnings Yield | -113.42 |